CalciMedica (CALC) Competitors

C4 Therapeutics (NASDAQ:CCCC) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment, dividends and community ranking.

Does the MarketBeat Community prefer CCCC or CALC?

C4 Therapeutics received 9 more outperform votes than CalciMedica when rated by MarketBeat users. However, 94.74% of users gave CalciMedica an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote.

Company	Underperform	Outperform
C4 Therapeutics	Outperform Votes 27 38.57%	Underperform Votes 43 61.43%
CalciMedica	Outperform Votes 18 94.74%	Underperform Votes 1 5.26%

Do institutionals & insiders have more ownership in CCCC or CALC?

78.8% of C4 Therapeutics shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by insiders. Comparatively, 41.5% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the media favor CCCC or CALC?

In the previous week, C4 Therapeutics and C4 Therapeutics both had 3 articles in the media. C4 Therapeutics' average media sentiment score of 0.97 beat CalciMedica's score of 0.60 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend CCCC or CALC?

C4 Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 782.35%. CalciMedica has a consensus target price of $18.00, indicating a potential upside of 928.57%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
CalciMedica	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings and valuation, CCCC or CALC?

CalciMedica has lower revenue, but higher earnings than C4 Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$39.78M	2.43	-$132.49M	-$1.47	-0.93
CalciMedica	N/A	N/A	-$34.36M	-$1.56	-1.12

Which has more risk & volatility, CCCC or CALC?

C4 Therapeutics has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Is CCCC or CALC more profitable?

CalciMedica has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-313.35%	-42.45%	-27.55%
CalciMedica	N/A	-164.24%	-103.53%

Summary

C4 Therapeutics beats CalciMedica on 9 of the 15 factors compared between the two stocks.